Hood River Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Hood River Capital Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-131,846	Closed	-$8.37M	–	117
2019 Q2	$8.37M	Buy	131,846 +4,765	+4%	+$303K	0.39%	83
2019 Q1	$8.81M	Sell	127,081 -5,385	-4%	-$308K	0.44%	84
2018 Q4	$5.76M	Buy	132,466 +1,903	+1%	+$104K	0.34%	85
2018 Q3	$9.97M	Sell	130,563 -816	-0.6%	-$66.4K	0.44%	82
2018 Q2	$10.1M	Buy	131,379 +5,149	+4%	+$333K	0.52%	80
2018 Q1	$6.44M	Buy	126,230 +3,039	+2%	+$153K	0.36%	84
2017 Q4	$5.71M	Buy	123,191 +8,897	+8%	+$436K	0.33%	81
2017 Q3	$6.09M	Buy	114,294 +1,998	+2%	+$118K	0.39%	81
2017 Q2	$6.97M	Buy	112,296 +2,667	+2%	+$161K	0.48%	75
2017 Q1	$7.43M	Sell	109,629 -48,761	-31%	-$3.72M	0.56%	74
2016 Q4	$11.1M	Buy	158,390 +48,099	+44%	+$3.41M	0.97%	42
2016 Q3	$7.82M	Buy	+110,291	New	+$7.04M	0.8%	57

Other funds holding RARE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Hood River Capital Management's RARE Position: Q3 2019 in Review

Hood River Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2019, closing a stake of 131,846 shares — an estimated $8.37M sold.

Hood River Capital Management first reported a position in RARE in Q3 2016 and held it in 12 quarters. The position peaked at $11.1M in Q4 2016. 172 funds tracked by Wall St. Rank hold RARE as of Q3 2019.

Hood River Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q3 2019 after selling out during the quarter.
Hood River Capital Management sold 131,846 Ultragenyx Pharmaceutical shares in Q3 2019, an estimated $8.37M.
Hood River Capital Management first reported a position in Ultragenyx Pharmaceutical in Q3 2016 and held it in 12 quarters.
Hood River Capital Management's Ultragenyx Pharmaceutical position peaked at $11.1M in Q4 2016.
172 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2019.

Based on Hood River Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.